Co‐Delivery of Precisely Prescribed Multi‐Prodrug Combination by an Engineered Nanocarrier enables Efficient Individualized Cancer Chemotherapy

• DOI: 10.1002/adma.202110490
• Publication Date: 2022-01-19T16:13:52Z
• Authors: Yuqiang Li; Yitong Jiang; Ziyan Zheng; Nan Du; Shuli Guan; Wenxuan Guo; Xiaohu Tang; Jiajunzi Cui; Lanqiong Zhang; Kunpeng Liu; Qingsong Yu; Zhihua Gan
• Keywords: Nanocarriers; Combination therapy

The limited anticancer drug library and the frequent occurrence of resistance have driven monotherapy-based cancer therapy into a difficult situation. Considering formidable process new discovery, combination using currently available drugs is potential alternative. Nevertheless, barrier between in vitro screening precise vivo delivery remains insurmountable current free-drug- or nanoparticle (NP)-based therapy, which substantially hinders application therapy. Herein, novel, strategy to realize efficient individualized proposed. Nanomedicine (NM) engineered microfluidics-based mixer by combining rationally designed polymeric prodrugs three commercial chemotherapeutics cascade-responsive block copolymer; NM possesses ratiometric loading synchronized release. In addition quantitative precisely controlled combination, consistent nanoproperties these NPs make their fate predictable. Consequently, tumor growth metastasis can be effectively inhibited prescribed derived from screening. This proof-of-concept study clearly reveals feasibility overcoming drug-library limitations through any predetermined facilitating translational research